Source link : https://newshealth.biz/health-news/survival-win-with-inavolisib-based-triplet-in-pik3ca-mutated-breast-cancer/
(MedPage Today) — CHICAGO — Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, endocrine-resistant disease… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115726 Author : Publish date : 2025-05-22 21:00:00 Copyright for syndicated content belongs to the linked Source.
The post Survival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast Cancer first appeared on News Health.
—-
Author : News Health
Publish date : 2025-05-22 21:00:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8